Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats.

Rossoni G, De Gennaro Colonna V, Bernareggi M, Polvani GL, Müller EE, Berti F

Journal of cardiovascular pharmacology1 Aug 1998Cited by 48 (Europe PMC)

PMID9700988DOI10.1097/00005344-199808000-00013PepBankPUB-09700988

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In aged rats, 21 days of hexarelin almost fully restored recovery of left ventricular developed pressure after ischemia, versus 37% in controls.
In plain wordsIn aged rats, hexarelin protected the heart: pressure recovered almost fully after a short blood flow stop, compared with saline-treated rats.
Peptide
Hexarelin
Outcome
IncreasePostischemic recovery of left ventricular developed pressure
Study
ratn = 9
Isolated hearts from 24-month-old male rats after in vivo treatment
Comparator
Saline-treated aged rats
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg, b.i.d. · subcutaneous · 21 daysAs given in this study (rat).
Measurements
LVDP recovery
90 % of preischemic values
hexarelin
LVDP recovery
37 % of preischemic values
saline controls
Source sentences
Summary
In fact, the recovery of LVDP at reperfusion was almost complete (90% of the preischemic values; from 93 +/- 5.8 to 83.7 +/- 5.9 mm Hg; p > 0.05; n = 9), and the increase in coronary resistance was minimal (from 67 +/- 5.8 to 79.7 +/- 6.9 mm Hg; p > 0.05; n = 9).
2 context sentences(design, population, supporting numbers)
Summary · context
a low recovery of postischemic left ventricular developed pressure (LVDP; 37% of the preischemic values; from 90 +/- 5.7 to 33.5 +/- 3.8 mm Hg
Summary · context
The ability of hexarelin, a recently synthesized hexapeptide with a strong growth hormone (GH)-releasing activity, or of GH itself to display a protectant activity against postischemic ventricular dysfunction in senescent hearts was studied in 24-month-old male rats.
Report a problemFND-0970098801
02AnimalAnimal study (in vivo)Efficacy outcome
In aged rats, hexarelin kept the postischemic increase in coronary perfusion pressure minimal, whereas controls showed a 71% increase.
In plain wordsIn aged rats, hexarelin kept the rise in coronary pressure after reduced blood flow small, compared with saline-treated rats.
Peptide
Hexarelin
Outcome
DecreasePostischemic increase in coronary perfusion pressure
Study
ratn = 9
Isolated hearts from 24-month-old male rats after in vivo treatment
Comparator
Saline-treated aged rats
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg, b.i.d. · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
and the increase in coronary resistance was minimal (from 67 +/- 5.8 to 79.7 +/- 6.9 mm Hg; p > 0.05; n = 9).
2 context sentences(design, population, supporting numbers)
Summary · context
coupled to a substantial increase in coronary perfusion pressure (CPP; 71% over baseline; from 68.3 +/- 5.2 to 116.8 +/- 4.6 mm Hg; p < 0.01; n = 10)
Summary · context
The ability of hexarelin, a recently synthesized hexapeptide with a strong growth hormone (GH)-releasing activity, or of GH itself to display a protectant activity against postischemic ventricular dysfunction in senescent hearts was studied in 24-month-old male rats.
Report a problemFND-0970098802
03AnimalAnimal study (in vivo)Efficacy outcome
In aged rats, hexarelin limited the postischemic increase of creatine kinase in perfusates to twofold, versus 6.6-fold in controls.
In plain wordsIn aged rats, hexarelin limited the release of a heart injury marker after reduced blood flow, compared with saline-treated rats.
Peptide
Hexarelin
Outcome
DecreaseCreatine kinase release in heart perfusates after ischemia
Study
ratn = 9
Isolated hearts from 24-month-old male rats after in vivo treatment
Comparator
Saline-treated aged rats
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg, b.i.d. · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
Furthermore, the concentration of CK in the perfusates was increased only twofold (from 45.8 +/- 5.5 to 90 +/- 7.2 mU/min/g wet tissue; p < 0.05; n = 9), with a gradual return toward basal values at the end of reperfusion.
2 context sentences(design, population, supporting numbers)
Summary · context
(b) a marked increase of creatine kinase (CK) released in the perfusates (6.6-fold increase over preischemic values
Summary · context
The ability of hexarelin, a recently synthesized hexapeptide with a strong growth hormone (GH)-releasing activity, or of GH itself to display a protectant activity against postischemic ventricular dysfunction in senescent hearts was studied in 24-month-old male rats.
Report a problemFND-0970098803
04AnimalAnimal study (in vivo)Efficacy outcome
In aged rats, the heart protection by hexarelin occurred without detectable change in pituitary GH mRNA.
In plain wordsIn aged rats, hexarelin protected the heart without a detectable change in pituitary growth hormone messenger RNA.
Peptide
Hexarelin
Outcome
No significant changePituitary GH mRNA
Study
ratn: not reported in source
Isolated hearts from 24-month-old male rats after in vivo treatment
Comparator
Saline-treated aged rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 microg/kg, b.i.d. · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
The protectant activity of hexarelin was divorced from any detectable alteration of the somatotropic function, as assessed by pituitary GH messenger RNA (mRNA) and plasma insulin-like growth factor I levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The ability of hexarelin, a recently synthesized hexapeptide with a strong growth hormone (GH)-releasing activity, or of GH itself to display a protectant activity against postischemic ventricular dysfunction in senescent hearts was studied in 24-month-old male rats.
Report a problemFND-0970098804
05AnimalAnimal study (in vivo)Efficacy outcome
In aged rats, the heart protection by hexarelin occurred without detectable change in plasma IGF-I.
In plain wordsIn aged rats, hexarelin protected the heart without a detectable change in blood IGF-I.
Peptide
Hexarelin
Outcome
No significant changePlasma IGF-I
Study
ratn: not reported in source
Isolated hearts from 24-month-old male rats after in vivo treatment
Comparator
Saline-treated aged rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 microg/kg, b.i.d. · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
The protectant activity of hexarelin was divorced from any detectable alteration of the somatotropic function, as assessed by pituitary GH messenger RNA (mRNA) and plasma insulin-like growth factor I levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The ability of hexarelin, a recently synthesized hexapeptide with a strong growth hormone (GH)-releasing activity, or of GH itself to display a protectant activity against postischemic ventricular dysfunction in senescent hearts was studied in 24-month-old male rats.
Report a problemFND-0970098805
06AnimalAnimal study (in vivo)Efficacy outcome
In aged rats, 6-keto-PGF1alpha release in heart perfusates did not differ among the control, hexarelin and GH groups.
In plain wordsIn aged rats, a heart prostacyclin marker did not differ between hexarelin, growth hormone and saline groups.
Peptide
Hexarelin
Outcome
No significant change6-keto-prostaglandin F1alpha release in heart perfusates
Study
ratn: not reported in source
Isolated hearts from 24-month-old male rats after in vivo treatment
Comparator
Saline-treated aged rats
Outcome group
Inflammation markers · Cardiovascular
Studied dose
80 microg/kg, b.i.d. · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
Evaluation of the rate of release of 6-keto-prostaglandin F1alpha (PGF1alpha), the stable metabolite of prostacyclin, in heart perfusates, and assessment of the vasopressor activity of angiotensin II on the coronary vasculature, did not show any change in these parameters among the three experimental groups.
1 context sentence(design, population, supporting numbers)
Summary · context
The ability of hexarelin, a recently synthesized hexapeptide with a strong growth hormone (GH)-releasing activity, or of GH itself to display a protectant activity against postischemic ventricular dysfunction in senescent hearts was studied in 24-month-old male rats.
Report a problemFND-0970098806
07AnimalAnimal study (in vivo)Efficacy outcome
In aged rats, the vasopressor activity of angiotensin II on the coronary vasculature did not differ among the control, hexarelin and GH groups.
In plain wordsIn aged rats, heart vessel response to angiotensin II did not differ between hexarelin, growth hormone and saline groups.
Peptide
Hexarelin
Outcome
No significant changeAngiotensin II vasopressor activity on coronary vasculature
Study
ratn: not reported in source
Isolated hearts from 24-month-old male rats after in vivo treatment
Comparator
Saline-treated aged rats
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg, b.i.d. · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
Evaluation of the rate of release of 6-keto-prostaglandin F1alpha (PGF1alpha), the stable metabolite of prostacyclin, in heart perfusates, and assessment of the vasopressor activity of angiotensin II on the coronary vasculature, did not show any change in these parameters among the three experimental groups.
1 context sentence(design, population, supporting numbers)
Summary · context
The ability of hexarelin, a recently synthesized hexapeptide with a strong growth hormone (GH)-releasing activity, or of GH itself to display a protectant activity against postischemic ventricular dysfunction in senescent hearts was studied in 24-month-old male rats.
Report a problemFND-0970098807
08AnimalAnimal study (in vivo)Efficacy outcome
In aged rats, hexarelin protection against myocardial stunning was far greater than that of GH.
In plain wordsIn aged rats, hexarelin protected the heart much more than growth hormone did.
Peptide
Hexarelin
Outcome
IncreaseHeart protection by hexarelin versus GH
Study
ratn: not reported in source
Isolated hearts from 24-month-old male rats after in vivo treatment
Comparator
Growth hormone
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg, b.i.d. · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
The protection afforded by the peptide is likely due to a direct cardiotropic action and is far greater than that of GH.
1 context sentence(design, population, supporting numbers)
Summary · context
The ability of hexarelin, a recently synthesized hexapeptide with a strong growth hormone (GH)-releasing activity, or of GH itself to display a protectant activity against postischemic ventricular dysfunction in senescent hearts was studied in 24-month-old male rats.
Report a problemFND-0970098808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.